

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

MINGYUAN MEDICARE DEVELOPMENT COMPANY LIMITED

銘源醫療發展有限公司*

(Incorporated in Bermuda with limited liability)

(Stock code: 0233)

UPDATE ON TRADING SUSPENSION

This announcement is made by Mingyuan Medicare Development Company Limited (the “**Company**”) pursuant to Rules 13.09(2) and 13.24A of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) and the provisions of inside information under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

Reference is made to:

- (i) the announcement of the Company dated 15 July 2015 in relation to the conditions for resumption of trading in the shares of the Company (the “**Shares**”) imposed by the Stock Exchange (the “**Resumption Conditions**”); and
- (ii) the announcements of the Company dated 10 August 2018, 6 November 2018 and 11 February 2019 in relation to updates on trading suspension (the “**Quarterly Updates**”).

(collectively, the “**Announcements**”)

Terms defined in the Announcements shall have the same meaning herein unless otherwise defined or the context otherwise required.

UPDATE ON RESUMPTION CONDITIONS

As set out in the Quarterly Updates, the Board has taken various acts to facilitate the fulfilment of the Resumption Conditions.

** For identification purpose only*

Audited Financial Results for the Years 2014 to 2018

The Company has been cooperating with its auditors to assist them in completing the audit procedures for the years 2014 to 2018. Following discussions with the auditors of the Company, the Board was informed that the audited report for the years 2014 to 2016 will be finalised by the end of May 2019, whilst the audit procedures for the years 2017 and 2018 are expected to be completed by the end of June 2019.

Additional Resumption Guidance

As announced by the Company on 18 April 2019, the Stock Exchange has considered it appropriate to require the Company, as an additional resumption guidance, to demonstrate a sufficient level of operations or assets under Rule 13.24 to warrant the continued listing of the Shares (the “**Additional Resumption Guidance**”). The Company is working closely with its auditors to ascertain its level of operations and assets for the year ended 31 December 2018 in order to fulfil the Additional Resumption Guidance.

UPDATE ON BUSINESS OPERATIONS

Since the last Quarterly Update dated 11 February 2019, the Company has continued to carry on its principal business in manufacturing and trading of HPV chips and related equipment through GPSZ in the PRC.

CONTINUED SUSPENSION OF TRADING

Trading in the Shares on the Stock Exchange will remain suspended until further notice.

By Order of the Board
Mingyuan Medicare Development Company Limited
LAM Ping Cheung
Chairman

Hong Kong, 2 May 2019

As at the date of this announcement, the Board comprises (i) Mr. Lam Ping Cheung and Mr. Hui Yip Wing as executive Directors and (ii) Ms. Chan Mee Sze, Mr. Lam Suk Ping, Ms. Fan Stephanie Winnie and Mr. Cheung Chi Ming as independent non-executive Directors.